Shifting the LDL-receptor paradigm in familial hypercholesterolemia: Novel insights from recent kinetic studies of apolipoprotein B-100 metabolism

Atherosclerosis Supplements

Volumn 2, Issue 3, 2002, Pages 1-4

  Barrett, P Hugh R ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cholesterol; Familial hypercholesterolemia; Low density lipoprotein

Indexed keywords

APOLIPOPROTEIN B100; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL SYNTHESIS; DOMINANT INHERITANCE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC VARIABILITY; HEREDITY; HUMAN; LIPOPROTEIN METABOLISM; LIPOPROTEIN SECRETION; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; BIOSYNTHESIS; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; LIVER; METABOLISM; PLASMAPHERESIS; RABBIT; RAT; REVIEW; SECRETION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL ESTERS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; LIVER; MODELS, ANIMAL; MODELS, BIOLOGICAL; PLASMAPHERESIS; RABBITS; RATS; RECEPTORS, LDL;

EID: 0036513349     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00012-5     Document Type: Article

References (31)

1. Goldstein J.L., Brown M.S. Atherosclerosis: the low-density lipoprotein receptor hypothesis. Metabolism. 26:1977;1257-1275.
2. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. Starburg J.B., Wyngaarden J.B., Fredrickson D.S. The molecular and metabolic basis of inhibited disease. 7th ed. 1999;1981-2020 McGraw Hill, New York.
3. Thompson G.R., Naoumova R.P., Watts G.F. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. 37:1996;439-447.
4. Sniderman A.D., Zhang X.-J., Cianflone K. Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. Atherosclerosis. 148:2000;215-229.
5. Sniderman A.D., Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb. 13:1993;629-636.
6. Dietschy J.M., Turley S.D., Spady D.K. Role of the liver in maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34:1993;1637-1659.
7. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:1993;883-893.
8. Horton J.D., Shimano H., Hamilton R.L., Brown M.S., Goldstein J.L. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103:1999;1067-1076.
9. Twisk J., Gillian-Daniel D.L., Wang L., Tebon A., Barrett P.H.R., Attie A.D. The role of the LDL receptor in apolipoproteinB secretion. J. Clin. Invest. 105:2000;521-532.
10. Hornick C.A., Kita T., Hamilton R.L., Kane J.P., Havel R.J. Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA. 80:1983;6096-6100.
11. Yamamoto T., Bishop R.W., Brown M.S., Goldstein J.L., Russell D.W. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science. 232:1986;1230-1237.
12. Janus E.D., Nicoll A.M., Turner P.R., Magill P., Lewis B. Kinetic bases of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur. J. Clin. Invest. 10:1980;161-172.
13. Fisher W.R., Zech L.A., Stacpoole P.W. ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm. Arterioscler. Thromb. 14:1994;501-510.
14. Cummings M.H., Watts G.F., Umpleby M., Hennessy T.R., Quiney J.R., Sönksen P.H. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolemia: a stable isotope study. Atherosclerosis. 113:1995;79-89.
15. Watts G.F., Cummings M.H., Umpleby M., Quiney J.R., Naoumova R., Thompson G.R., Sönksen P.H. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolemia: pathophysiological and therapeutic implications. Eur. J. Clin. Invest. 25:1995;559-567.
16. Zulewski H., Ninnis R., Miserez A.R., Baumstark M.W., Keller U. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100. J. Lipid Res. 39:1998;380-387.
17. Thompson G.R., Spinks T., Ranicar A., Myant N.B. Non-steady-state studies of low-density lipoprotein turnover in familial hypercholesterolemia. Clin. Sci. Mol. Med. 52:1977;361-369.
18. Pfohl M., Naoumova R.P., Klass C., Knisel W., Jakober B., Risler T., Thompson G.R. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35:1994;1946-1955.
19. Pfohl M., Naoumova R.P., Neuwirth C., Sussekov A., Smykowski J., Rendell N.B., Taylor G.W., Seif F.J., Thompson G.R. Upregulation of cholesterol synthesis after acute reduction of low density lipoprotein by apheresis in normocholesterolemic subjects: evidence for a threshold effect. Atherosclerosis. 135:1997;257-262.
20. Parhofer K.G., Barrett P.H.R., Demant T., Richter W.O., Schwandt P. Weekly LDL apheresis has no effect on apoB metabolic parameters in heterozygous familial hypercholesterolemia. J. Lipid Res. 37:1996;2383-2393.
21. Barrett P.H.R., Parhofer K.G. Low-density lipoprotein-apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics. Metabolism. 47:1998;478-483.
22. Pietzsch J., Wiedemann B., Julius U., Nitzsche S., Gehrisch S., Bergmann S., Leonhardt W., Jaross W., Hanefeld M. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach. J. Lipid Res. 37:1996;2074-2087.
23. Schaefer J.R., Scharnagl H., Baumstark M.W., Schweer H., Zech L.A., Seyberth H., Winkler K., Steinmetz A., März W. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler. Thromb. Vasc. Biol. 17:1997;348-353.
24. Parhofer K.G., Barrett P.H.R., Demant T., Richter W.O., Schwandt P. Weekly LDL apheresis has no effect on apoB metabolic parameters in heterozygous familial hypercholesterolemia. J. Lipid Res. 37:1996;2383-2393.
25. Soutar A.K. Update on low density lipoprotein receptor mutations. Curr. Opin. Lipidol. 9:1998;141-147.
26. Nicholls P., Young I.S., Graham C.A. Genotype/phenotype correlations in familial hypercholesterolemia. Curr. Opin. Lipidol. 9:1998;313-317.
27. Gudnason V., Day I.N., Humpries S.E. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler. Thromb. 14:1994;1717-1722.
28. Sniderman A., Shapiro S., Marpole D., Skinner B., Teng B., Kwiterovich P.O. Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia. Proc. Natl. Acad. Sci. USA. 97:1980;604-608.
29. Seed M., Hoppichler F., Reaveley D., McCarthy S., Thompson G.R., Boerwinkle E., Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. New Engl. J. Med. 322:1990;1494-1499.
30. Cabezas M.C., Bruin T.W.A., Westerveld H.E., Meijer E., Erkelens D.W. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolemia. J. Intern. Med. 244:1998;299-307.
31. Grundy S.M. HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia. New Engl. J. Med. 319:1988;24-33.